secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sanara MedTech Inc. (SMTI)
CIK:        0000714256
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001493152-23-028632
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanara MedTech Q2 revenue up 63% to $15.8M; acquires collagen assets to cut royalties
--------------------------------------------------------------------------------

- Q2 2023 net revenues $15.8M (+63% YoY); net loss $1.9M vs net income $0.8M in prior year.
- Completed post-quarter acquisition of collagen-related assets including CellerateRX Surgical and HYCOL.
- Annual royalties on collagen products were $1.8M in 2022; acquisition expected to eliminate those payments.
- Products sold in over 950 facilities and contracted in 3,000+ hospitals/ASCs as of June 30.
- Loss before income taxes improved to $1.9M from $3.4M in Q2 2022 due to slower expense growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/714256/000149315223028632/0001493152-23-028632-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/714256/000149315223028632/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-028632

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer